Fate Therapeutics (FATE) Misses Q2 EPS by 6c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.37), $0.06 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.18 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c
• Independent Bank receives regulatory approval for HCB Financial acquisition